Semaglutide
Ozempic, Rybelsus, Wegovy
A long-acting GLP-1 receptor agonist used for type 2 diabetes and obesity management by enhancing insulin secretion and suppressing appetite.
Not Yet Recruiting
PHASE2, PHASE3
NCT05646199
Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
University of Hull
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NA
NCT05040087
Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)
Foundation for Atlanta Veterans Education and Research, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT05813249
Semaglutide in Nonalcoholic Fatty Liver Disease
Zagazig University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04524832
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05232708
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE1, PHASE2
NCT04702516
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture
Morten Frost
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT04538352
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D
The Cleveland Clinic
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NA
NCT05196958
Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease
Fondation Hôpital Saint-Joseph
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT06234111
Semaglutide and Physical Activity for Obesity and Multimorbidity
Hvidovre University Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05689099
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT03985384
Semaglutide Treatment On Coronary Progression
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT02453711
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05035095
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT01720446
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT05768945
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
Brigham and Women's Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07036172
Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT07251556
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Chinese University of Hong Kong
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04865770
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03010475
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Enrolling By Invitation
NCT05503927
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
Novo Nordisk A/S
OBSERVATIONAL
Updated Dec 15, 2025